Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
6.37
-0.19 (-2.90%)
At close: Aug 10, 2026, 4:00 PM EDT
6.37
0.00 (0.00%)
After-hours: Aug 10, 2026, 4:58 PM EDT
Taysha Gene Therapies Revenue
Taysha Gene Therapies had revenue of $7.47M in the twelve months ending March 31, 2026, up 3.42% year-over-year. In the year 2025, Taysha Gene Therapies had annual revenue of $9.77M with 17.28% growth.
Revenue (ttm)
$7.47M
Revenue Growth
+3.42%
P/S Ratio
272.72
Revenue / Employee
$75,465
Employees
99
Market Cap
2.04B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.77M | 1.44M | 17.28% |
| Dec 31, 2024 | 8.33M | -7.12M | -46.07% |
| Dec 31, 2023 | 15.45M | 12.95M | 517.55% |
| Dec 31, 2022 | 2.50M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 959.90M |
| ADMA Biologics | 512.28M |
| Aurinia Pharmaceuticals | 311.51M |
| AbCellera Biologics | 66.17M |
| Mesoblast | 65.38M |
| Ocular Therapeutix | 52.06M |
| Stoke Therapeutics | 27.59M |
| Zenas BioPharma | 10.00M |
TSHA News
- 3 days ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11 - GlobeNewsWire
- 7 days ago - Taysha Gene Therapies, Catalent announce commercial supply pact for TSHA-102 - TheFly
- 7 days ago - Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome - GlobeNewsWire
- 20 days ago - Taysha Gene Therapies price target raised to $13 from $11 at Goldman Sachs - TheFly
- 4 weeks ago - Taysha Gene Therapies falls -11.0% - TheFly
- 5 weeks ago - Taysha Gene Therapies Slides: Corporate presentation - Filings
- 5 weeks ago - Taysha Gene Therapies price target raised to $15 from $12 at Baird - TheFly